<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348683</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1441</org_study_id>
    <nct_id>NCT03348683</nct_id>
  </id_info>
  <brief_title>Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients</brief_title>
  <official_title>Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients: a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, prospective trial will be offered to women admitted to the labor floors at
      Mount Sinai Medical Center for labor induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of labor is a common obstetric procedure, which is performed to provoke the onset
      of labor and lead to delivery of the fetus. While some early studies suggested a possible
      increased rate of cesarean with induction of labor, more recent meta-analyses have shown that
      induction does not influence this rate. There is data from small randomized studies that
      demonstrates the effectiveness of propranolol, a non-selective beta-blocker, for induction of
      labor. This literature suggests a decrease in the amount of time to delivery and a possible
      reduction in cesarean section rates when propranolol is used in conjunction with oxytocin for
      induction of labor compared to oxytocin alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Study drug and placebo will be randomized and mixed to appear identical by the Mount Sinai Investigational Drug Service (IDS). The randomization code will be kept by the lead pharmacist of the IDS until completion of the trial, at which point data will be unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Beginning of Induction to Delivery</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Various Mode of Delivery</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Latent</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>Time of latent labor defined as &lt;6cm of cervical dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maternal Morbidity Composite Score = 1</measure>
    <time_frame>average of 24 hours</time_frame>
    <description>Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission.
The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postpartum Hemorrhage</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Fetus With Heart Rate Decelerations</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Fetus With Fetal Bradycardia</measure>
    <time_frame>30 minutes from drug administration</time_frame>
    <description>Count of fetus with fetal bradycardia (&lt;110bpm for &gt;10 minutes within 30 minutes of study drug administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Neonatal Outcome Composite Score = 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death.
The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Hypoglycemia</measure>
    <time_frame>Day 1</time_frame>
    <description>Neonatal outcome - Number of neonates with hypoglycemia (blood glucose &lt;50).
This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg of IV push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>an equivalent quantity in milliliters of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous women undergoing induction of labor

          -  &gt;37 weeks' gestational age

          -  Non-anomalous, singleton cephalic presenting fetus.

        Exclusion Criteria:

          -  Multiple gestations, known fetal anomalies

          -  Maternal cardiac or hypertensive disease

          -  Chronic beta blocker use

          -  Bronchial asthma

          -  Maternal or fetal indication for immediate delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant patients are the only subjects eligible for study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Stone, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>BLACK JW, CROWTHER AF, SHANKS RG, SMITH LH, DORNHORST AC. A NEW ADRENERGIC BETARECEPTOR ANTAGONIST. Lancet. 1964 May 16;1(7342):1080-1.</citation>
    <PMID>14132613</PMID>
  </reference>
  <reference>
    <citation>Moghadam AD, Jaafarpour M, Khani A. Comparison effect of oral propranolol and oxytocin versus oxytocin only on induction of labour in nulliparous women (a double blind randomized trial). J Clin Diagn Res. 2013 Nov;7(11):2567-9. doi: 10.7860/JCDR/2013/5704.3613. Epub 2013 Nov 10. Erratum in: J Clin Diagn Res. 2015 Aug;9(8):ZZ01.</citation>
    <PMID>24392402</PMID>
  </reference>
  <reference>
    <citation>Kashanian M, Fekrat M, Zarrin Z, Ansari NS. A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). J Obstet Gynaecol Res. 2008 Jun;34(3):354-8. doi: 10.1111/j.1447-0756.2008.00790.x.</citation>
    <PMID>18588611</PMID>
  </reference>
  <reference>
    <citation>Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD. Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2016 Apr;293(4):721-9. doi: 10.1007/s00404-015-3991-8. Epub 2015 Dec 22. Review.</citation>
    <PMID>26695642</PMID>
  </reference>
  <reference>
    <citation>Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15;135(4):485-9.</citation>
    <PMID>573555</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Ramos L, Quillen MJ, Kaunitz AM. Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor. Obstet Gynecol. 1996 Oct;88(4 Pt 1):517-20.</citation>
    <PMID>8841209</PMID>
  </reference>
  <reference>
    <citation>Ikeda S, Tamaoki H, Akahane M, Nebashi Y. Effects of ritodrine hydrochloride, a beta 2-adrenoceptor stimulant, on uterine motilities in late pregnancy. Jpn J Pharmacol. 1984 Jul;35(3):319-26.</citation>
    <PMID>6482092</PMID>
  </reference>
  <reference>
    <citation>Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, Torp-Pedersen C, Poulsen HE. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012 Jul 19;2(4). pii: e001185. doi: 10.1136/bmjopen-2012-001185. Print 2012.</citation>
    <PMID>22815467</PMID>
  </reference>
  <reference>
    <citation>Omar HA, Rhodes LA, Ramirez R, Arsich J, Einzig S. Alteration of human placental vascular tone by antiarrhythmic medications in vitro. J Cardiovasc Electrophysiol. 1996 Dec;7(12):1197-203.</citation>
    <PMID>8985808</PMID>
  </reference>
  <reference>
    <citation>Palomäki O, Uotila J, Tammela O, Kaila T, Lavapuro M, Huhtala H, Tuimala R. A double blind, randomized trial on augmentation of labour with a combination of intravenous propranolol and oxytocin versus oxytocin only. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):44-9. Epub 2005 Jul 26.</citation>
    <PMID>16051416</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>December 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2019</results_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>joanne stone</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Induction</keyword>
  <keyword>Labor</keyword>
  <keyword>Propranolol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03348683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First enrollment 12-11-2017, final enrollment 12/11/2018. Enrollment occurred on the labor floor of the Mount Sinai Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Propranolol</title>
          <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propranolol</title>
          <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.70" spread="5.72"/>
                    <measurement group_id="B2" value="31.61" spread="6.37"/>
                    <measurement group_id="B3" value="31.66" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) at admission</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.04" spread="5.34"/>
                    <measurement group_id="B2" value="28.89" spread="4.40"/>
                    <measurement group_id="B3" value="28.97" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age (GA) at admission</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" lower_limit="39" upper_limit="40.9"/>
                    <measurement group_id="B2" value="40.1" lower_limit="39.3" upper_limit="40.9"/>
                    <measurement group_id="B3" value="40.0" lower_limit="39.1" upper_limit="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Private Insurance</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>In vitro Fertilization (IVF)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fetal Growth Restriction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Beginning of Induction to Delivery</title>
        <description>The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.</description>
        <time_frame>average of 24 hours</time_frame>
        <population>N=154 - only those who delivered vaginally</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Beginning of Induction to Delivery</title>
          <description>The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.</description>
          <population>N=154 - only those who delivered vaginally</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="5.4"/>
                    <measurement group_id="O2" value="14.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Various Mode of Delivery</title>
        <description>Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section</description>
        <time_frame>average of 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Various Mode of Delivery</title>
          <description>Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spontaneous vaginal delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vacuum assisted vaginal delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forceps assisted vaginal delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cesarean section</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Latent</title>
        <description>Time of latent labor defined as &lt;6cm of cervical dilation.</description>
        <time_frame>average of 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Latent</title>
          <description>Time of latent labor defined as &lt;6cm of cervical dilation.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="5.0"/>
                    <measurement group_id="O2" value="11.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maternal Morbidity Composite Score = 1</title>
        <description>Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission.
The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.</description>
        <time_frame>average of 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maternal Morbidity Composite Score = 1</title>
          <description>Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission.
The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postpartum Hemorrhage</title>
        <description>Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section</description>
        <time_frame>30 minutes from drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postpartum Hemorrhage</title>
          <description>Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Fetus With Heart Rate Decelerations</title>
        <description>Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration</description>
        <time_frame>30 minutes from drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fetus With Heart Rate Decelerations</title>
          <description>Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Fetus With Fetal Bradycardia</title>
        <description>Count of fetus with fetal bradycardia (&lt;110bpm for &gt;10 minutes within 30 minutes of study drug administration)</description>
        <time_frame>30 minutes from drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fetus With Fetal Bradycardia</title>
          <description>Count of fetus with fetal bradycardia (&lt;110bpm for &gt;10 minutes within 30 minutes of study drug administration)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Neonatal Outcome Composite Score = 1</title>
        <description>Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death.
The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Neonatal Outcome Composite Score = 1</title>
          <description>Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death.
The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Hypoglycemia</title>
        <description>Neonatal outcome - Number of neonates with hypoglycemia (blood glucose &lt;50).
This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)</description>
        <time_frame>Day 1</time_frame>
        <population>This population includes the neonates who had heelsticks to check their blood glucose.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Hypoglycemia</title>
          <description>Neonatal outcome - Number of neonates with hypoglycemia (blood glucose &lt;50).
This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)</description>
          <population>This population includes the neonates who had heelsticks to check their blood glucose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Propranolol</title>
          <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Fetal bradycardia</sub_title>
                <description>Fetal bradycardia within 30 minutes of study drug</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Fetal heart rate decelerations</sub_title>
                <description>Fetal heart rate decelerations within 30 minutes of study drug</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Maternal hypotension</sub_title>
                <description>Maternal hypotension &lt;80/40 within 30 minutes of study drug (no pressors required)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Catherine A Bigelow</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>651-206-9069</phone>
      <email>cassie.bigelow@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

